A Two-Year Clock Just Started for Pharmaceutical Importers
On July 22, 2026, the Trump administration fired its most consequential shot yet at the global pharmaceutical supply chain. Generic drugs — the medicines that fill roughly nine out of every ten prescriptions written in the United States — are now operating under a formal tariff countdown. President Donald Trump announced a plan to impose a 100 percent tariff on generic drugs starting in August 2028 as part of a bid to push pharmaceutical production back to the United States. The tariff would then jump to 200 percent in 2029. For importers, freight forwarders, and pharmaceutical supply chain managers, understanding this timeline — and acting on it now — is not optional.
What Exactly Was Announced
Trump said generic drugs imported into the U.S. will face zero tariffs for two years from August 1, before the rate rises to 100% in 2028, then doubles a year later. The structure is deliberately staged to give manufacturers time to make decisions. The announcement gives manufacturers a two-year runway before tariffs begin increasing, allowing companies time to decide whether to build or expand U.S. production facilities or continue importing products while facing substantially higher duties.
The White House said the policy will be implemented under Section 232 authority, giving drugmakers two years to shift generic drug production to the U.S. before tariffs rise. Section 232 of the Trade Expansion Act of 1962 allows the executive branch to impose import restrictions on national security grounds — the same legal tool already applied to branded pharmaceuticals earlier this year.
How This Fits Into the Broader Pharma Tariff Picture
This announcement does not exist in isolation. On April 2, 2026, President Trump issued a Proclamation invoking Section 232 of the Trade Expansion Act of 1962 to impose tariffs on imports of patented pharmaceuticals, biologics, and associated ingredients into the U.S. Generic pharmaceuticals, biosimilars, and their associated ingredients are expressly excluded from Section 232 tariffs at this time. Today's announcement is the explicit bridge between that exemption and its eventual end.
For covered products imported by 17 identified large pharmaceutical companies in Annex III of the Proclamation, the tariffs on patented drugs will become effective on July 31, 2026, while for all other importers the new 100% tariffs will become effective on September 29, 2026. Generic importers are watching those branded-drug deadlines land in real time — and they now know their own deadline is August 2028.
Commerce is required, within one year of the Proclamation, to advise the President whether circumstances indicate a need to extend Section 232 tariffs to generic pharmaceuticals and associated ingredients. That review window closes in April 2027 — well before the 2028 tariff trigger — meaning the policy landscape could shift again before the duties actually land.
Why Generic Drugs Are So Exposed
The vulnerability of this supply chain is extraordinary. India and China are increasingly the leading U.S. source for generic pharmaceuticals, which account for 91% of all prescriptions written in the U.S. The stakes are high for India, which ships around one-third of its pharma exports to the U.S.
The dependency runs even deeper than finished drug shipments. India produces about 35% of the active pharmaceutical ingredients, or APIs, for generics in the entire world, yet most Indian drugmakers rely on China for about 70% of the raw ingredients needed to manufacture these medicines. Approximately 70% of India's API needs — and up to 90% for critical antibiotics like cephalosporins and penicillin — are met by Chinese imports. A tariff on a finished generic drug import is therefore also a tariff on a supply chain that traces back through multiple continents and raw-material dependencies.
The move would upend a global supply chain that keeps generic medicines affordable for Americans. These off-patent drugs run the gamut from everyday painkillers and antibiotics to cholesterol and cancer drugs, and they are mostly produced at factories in India, Europe, and China.
The Margin Problem That Makes This Different
What separates generic drug tariffs from most other import duty scenarios is the business economics of the sector itself. Generic pharmaceuticals account for 91% of prescriptions written but only about 16% of revenue in the industry, while branded pharmaceuticals account for less than 10% of the prescriptions but over 80% of the revenue. Unlike branded drugmakers, generic manufacturers have almost no pricing cushion to absorb a 100% tariff.
With margins on many ordinary generics already razor-thin, some manufacturers may exit specific products entirely if wholesalers refuse to absorb or pass through the added cost, making the particular products no longer commercially viable. While brand-name pharmaceutical companies may have the resources to continue operations with rising costs, those that manufacture generic drugs will not. Generic manufacturers do not have this financial flexibility, which makes their ability to absorb new costs difficult. If generic manufacturers cannot keep up with rising costs, they may be forced to exit the market, leading to shortages of generic drugs that Americans rely on.
In Q1 of 2024, drug shortages reached an all-time high of 323, 70% of which were generic medications. Tariff-driven exit of smaller generic producers would compound a problem that already exists.
The Legal and Political Uncertainty Layer
Importers should not treat the 2028 date as a certainty carved in stone. Several forces could reshape the final policy before it bites.
It is also unclear what legal authority Trump will use to impose the planned tariffs on generic drugs, particularly the projected 200% tariff, which would take effect in August 2029, several months after the end of what should be his final term in office.
The two-year runway offers a critical negotiating window for New Delhi to push for tariff relief in its ongoing talks with the U.S., including by pledging corporate investment commitments in America. With the stated tariffs not biting until 2028 — an election year in the U.S. — New Delhi would hope that this rule will not be implemented.
That uncertainty is itself a supply chain risk. Importers who assume the tariffs will disappear and make no contingency plans may find themselves scrambling if the policy holds. Importers who front-load inventory or restructure sourcing prematurely may absorb unnecessary costs if tariffs are negotiated away.
What Pharmaceutical Importers Should Be Doing Right Now
The two-year window is valuable only if it is used. Pharmaceutical manufacturers, importers, and supply chain participants should promptly classify products, including APIs. Confirming whether imported pharmaceutical products, active pharmaceutical ingredients, and key raw materials are classifiable under the relevant HTSUS provisions is an immediate priority.
Beyond classification, the strategic decisions are significant. The phased schedule creates three distinct planning horizons. Through August 2028, the cost environment is unchanged — zero additional tariff — so this is the window to negotiate long-term supplier contracts with tariff-clause protections, evaluate alternative sourcing geography, model total landed cost under the 100% and 200% scenarios, and engage customs broker partners to ensure HTS classifications are bulletproof before the duties activate.
Immediate, broad-based price increases from pharmaceutical tariffs are unlikely in the near term due to existing exemptions, gradual implementation timelines, and available exception pathways. That breathing room should be used for preparation, not complacency.
Importers should evaluate the generic and biosimilar exclusion's durability, since Commerce is required within one year of the Proclamation to advise the President whether circumstances indicate a need to extend Section 232 tariffs to these products. Companies with generic or biosimilar portfolios should track these developments closely.
How ASR Can Help
Navigating a tariff environment this complex — especially one with phased deadlines, HTS classification stakes, and origin-of-manufacture questions layered across India, China, and Europe — demands a freight forwarder that moves quickly and knows where the pressure points are. ASR WorldWide Express coordinates pharmaceutical import shipments and connects clients with licensed customs broker partners to ensure proper classification, origin documentation, and compliance strategy as the Section 232 generic drug timeline develops.
Whether you are importing finished-dose generics, active pharmaceutical ingredients, or key starting materials, our team can help you map your current exposure, model cost scenarios for 2028, and build the supply chain flexibility to respond as policy evolves.
Call us at +1 786 373 3003 or email shipping@asrwe.com to speak with our team today.
Important Disclaimer
This article is informational only and does not constitute legal, tax, or customs compliance advice. Tariff policy affecting pharmaceutical imports under Section 232 remains subject to change through regulatory review, legislative action, and ongoing trade negotiations. Importers and life sciences supply chain managers should consult a licensed customs broker and qualified trade counsel for guidance specific to their products and business circumstances.
